172 related articles for article (PubMed ID: 12092212)
1. [18F FDG PET- applications in oncology].
Răileanu I; Rusu V; Stefănescu C; Cinotti L
Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):638-45. PubMed ID: 12092212
[TBL] [Abstract][Full Text] [Related]
2. [18F FDG PET-Applications in Oncology].
Răileanu I; Rusu V; Stefănescu C; Cinotti L; Hountis D
Rev Med Chir Soc Med Nat Iasi; 2002; 106(1):14-23. PubMed ID: 12635354
[TBL] [Abstract][Full Text] [Related]
3. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
4. Clinical applications of FDG-PET in oncology.
Czernin J
Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
[TBL] [Abstract][Full Text] [Related]
5. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
Giorgetti A; Volterrani D; Mariani G
Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of FDG-PET in oncology].
Sasaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
[TBL] [Abstract][Full Text] [Related]
7. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
Reske SN; Kotzerke J
Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
[TBL] [Abstract][Full Text] [Related]
9. [Positron-emission tomography in oncology].
Zaplatnikov K; Menzel C; Döbert N; Diehl M; Hamscho N; Grünwald F
Klin Med (Mosk); 2003; 81(12):13-21. PubMed ID: 14971150
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
11. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
12. [Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
Comans EF; Hoekstra OS; Hoekman K; van der Hoeven JJ; Golding RP; Teule GJ
Ned Tijdschr Geneeskd; 2000 Aug; 144(32):1520-8. PubMed ID: 10949634
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography: clinical applications in oncology. Part 1.
Kumar R; Nadig MR; Chauhan A
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1079-94. PubMed ID: 16336099
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
15. Clinical role of positron emission tomography in oncology.
Bomanji JB; Costa DC; Ell PJ
Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
[TBL] [Abstract][Full Text] [Related]
16. [Present status of PET images: clinical FDG PET in oncology].
Inoue T
Nihon Igaku Hoshasen Gakkai Zasshi; 1999 Nov; 59(13):737-44. PubMed ID: 10614103
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography imaging in evaluation of cancer patients.
Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
20. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
Choi JY; Lee KS; Kwon OJ; Shim YM; Baek CH; Park K; Lee KH; Kim BT
J Clin Oncol; 2005 Oct; 23(30):7654-9. PubMed ID: 16234527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
